Abstract:Approximately 80% of ductal carcinoma in situ (DCIS) and invasive breast cancers express hormone receptors (HR), and are typically treated with selective estrogen receptor modulators (SERMs) or aromatase inhibitors, or with additional HR-targeting agents in the research setting. However, the development of resistance poses a significant challenge. To better understand the mechanisms behind endocrine resistance and explore new treatment strategies, it is essential to have a reliable model system that accurately reflects the heterogeneous nature of breast lesions. In this study, we developed a protocol to generate patient-derived organoid cultures of pre-invasive and malignant breast lesions from patients with persistent or residual disease in the active surveillance or neoadjuvant setting after treatment with endocrine therapy. We generated n = 11 HR+ DCIS and n = 18 HR+ breast cancer organoids and used single-cell RNA-sequencing to characterize cell heterogeneity within individual organoid cultures. We observed mixed non-cancerous and malignant cells present within some cultures, and optimized protocols to minimize non-cancerous cell types. To better define endocrine sensitivity versus resistance, we also assessed responsiveness to estrogen and anti-estrogen therapy in individual cultures by monitoring organoid growth through live cell imaging and evaluating estrogen-response markers at the protein and RNA levels in response to treatment in vitro. Next, we applied our model system to evaluate endocrine resistance in heterogeneous tumor populations. We compared changes in cellular composition and signaling pathways in endocrine-resistant and endocrine-sensitive breast organoids based on in vitro metrics and/or correlation with clinical variables. In addition, within single cultures heterogeneous cell populations were identified with differential expression of ESR1 and HR target genes, generally falling into three cluster groups that could be defined based on different patterns of FOXA1, GATA3, TFF1, and XBP1 expression, among others. These populations also differed with evidence of co-expressed genes and signaling pathways related to breast tumorigenesis and differentiation (estrogen response, androgen response, mTOR signaling, metabolism) in putative HR-active cell populations in both pre-invasive and invasive breast cases. In summary, our study demonstrates that patient-derived breast and breast cancer organoids can be used to model estrogen responsiveness and endocrine resistance. We have established a platform that enables us to investigate the mechanisms underlying endocrine resistance at different premalignant and tumor stages to evaluate new treatment approaches. The ultimate goal of this work is to contribute to the development of new targeted therapies for endocrine-resistant breast lesions. Citation Format: Nadine Goldhammer, Shruti Warhadpande, Liana Beld, Cristian K. Maldonado Rodas, Allison Lam, Tam Binh Bui, Shoko Emily Abe, Michael Alvarado, Cheryl Ewing, Karen Goodwin, Rita Mukhtar, Jasmine Wong, Lamorna Brown Swigart, Gillian Hirst, Christopher Schwartz, Laura van't Veer, Laura Esserman, Jo Chien, Jennifer M. Rosenbluth. Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1) nr A059.

Abstract A062: Somatic engineering of rat models to recapitulate human breast cancer evolution and heterogeneity

Abstract PR02: Modeling breast cancer through somatic precision gene editing with high flexibility and efficiency

Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy

Abstract 3906: Ex vivo breast tumors for understanding the patient specific tumor microenvironment remodeling and drug responses

Abstract IA16: Creation and preliminary analyses of a full spectrum of breast cancers initiated de novo from normal human mammary cells

Abstract PR10: Mammary epithelial architecture modulates field cancerization

Abstract 3267: Human population based engineered breast tumor model for in vivo biomarker discovery

Abstract 941: Patient-derived model systems of endometrial cancers for disease modeling and drug sensitivity testing

Abstract 116: A novel murine model for interrogating tumor heterogeneity in non-small cell lung cancer

Abstract IA05: Leveraging preclinical models of triple negative breast cancer for translational research

Abstract PHB04: Predictive modeling, applied to genetically engineered mouse models of breast or lung cancer, provides insights into major oncogenic pathways

Abstract 2826: Examples of translational preclinical models to mimic cancer drug resistance

Abstract A065: Single cell transcriptomics reveals putative tumor promoting subpopulation in Brca1 mutant breast cancer mouse model

Rat Models of Hormone Receptor-Positive Breast Cancer

Abstract IA01: Modeling and understanding tumor biologic mechanisms

A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast Cancer

Abstract 6772: A 3D model of breast cancer-bone metastasis to mimic dysregulation of bone remodeling and drug response

Abstract 6625: Development of novel mixed-cell models to capture heterogeneity in castration-resistant prostate cancer

Abstract 265: Reconstructing the early steps of breast tumor initiation

Abstract B026: Targeting wild type and ESR1 mutations as neoantigens in hormone receptor positive breast cancer

Serial Transplantation of NMU-induced Rat Mammary Tumors: a Model of Human Breast Cancer Progression.